🔎 Trials Near Me

Home › Mga Sakit sa Baga › Massachusetts › Boston

Pag-aaral pangklinika para sa Mga Sakit sa Baga sa Boston, MA

14 pag-aaral para sa Mga Sakit sa Baga ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Boston (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Nagre-recruitPhase 2
  • Brigham and Women's Hospital, Boston
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07759245

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Nagre-recruitPhase 3
  • Boston Medical Center, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06119581

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

Nagre-recruit
  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 23, 2026 · NCT02984761

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Nagre-recruitPhase 3
  • Brigham and Women's Hospital, Boston
Edad 12 pataas · Lahat ng kasarian · Na-update Okt 15, 2026 · NCT06679140

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

Nagre-recruitPhase 3
  • Brigham and Women's Hospital, Boston
  • Clinical Trials Center, Boston
  • Clinical Trials Hub, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 14, 2026 · NCT07013474

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Nagre-recruitPhase 2
  • Beth Israel Deaconess Medical Center, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT05967689

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Nagre-recruitPhase 3
  • Dana-Farber Cancer Institute, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06765109

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Nagre-recruitPhase 1/2
  • Dana Farber Cancer Institute, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06128551

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Nagre-recruitPhase 2
  • Clinical Research Site, Boston
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07333183

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Nagre-recruitPhase 2
  • Dana-Farber Cancer Institute, Boston
  • Boston Children's Hospital, Boston
  • Brigham and Women's Hospital, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 10, 2026 · NCT05922761

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Nagre-recruitPhase 1/2
  • Massachusetts General Hospital,, Boston
Edad 12 pataas · Lahat ng kasarian · Na-update May 27, 2026 · NCT03093116

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Nagre-recruitPhase 2
  • Dana-Farber Cancer Institute, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 15, 2025 · NCT06619561

Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System

Nagre-recruit
  • Brigham and Women's Hospital, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2025 · NCT04555161

Pag-aaral para sa Mga Sakit sa Baga sa ibang lungsod

Iba pang pag-aaral sa Boston

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.